Lulizumab pegol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lulizumab pegol
Monoclonal antibody
Type?
SourceHumanized
Targetglycoprotein CD28
Clinical data
SynonymsBMS-931699
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC552H859N149O164S4
Molar mass52 kg/mol g·mol−1

Lulizumab pegol (BMS-931699) (INN[1]) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.

References[edit]

  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.